4D Molecular Therapeutics (FDMT) Cash from Operations Growth (1y) (2021 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 42.76% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.58% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 151.70% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 100.14% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 56.79% |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | -61.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -61.37% |
| Mar 31, 2026 | -42.65% |
| Dec 31, 2025 | 162.25% |
| Sep 30, 2025 | -58.20% |
| Jun 30, 2025 | -43.43% |
| Mar 31, 2025 | -64.18% |
| Dec 31, 2024 | -86.06% |
| Sep 30, 2024 | -2,409.91% |
| Jun 30, 2024 | -37.06% |
| Mar 31, 2024 | -4.24% |
| Dec 31, 2023 | -10.97% |
| Sep 30, 2023 | 94.43% |
| Jun 30, 2023 | -10.86% |
| Mar 31, 2023 | -18.50% |
| Dec 31, 2022 | -1.73% |
| Sep 30, 2022 | -33.69% |
| Jun 30, 2022 | -22.83% |
| Mar 31, 2022 | -53.20% |
| Dec 31, 2021 | -24.78% |
| Sep 30, 2021 | -17.58% |